FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096487127> ?p ?o ?g. }

• W2096487127 endingPage "1782" @default.
• W2096487127 startingPage "1776" @default.
• W2096487127 abstract "BackgroundPhase I and pharmacokinetic study to determine the maximal tolerated dose and the recommended dose, as well as the optimal sequence of a carboplatin/oxaliplatin combination delivered every 3 weeks.Patients and methodsPatients received either carboplatin [area under the curve (AUC)-based individually calculated dose (starting dose AUC 4 mg·min/ml), 1 h intravenous (i.v.) infusion] followed by oxaliplatin(110 mg/m2, 2 h i.v. infusion), every 3 weeks, or the reverse sequence.ResultsSixteen patients were included and only one dose level was assessed. In group A, 10 patients received 23 cycles of carboplatin followed by oxaliplatin. In group B, 6 patients received 20 cycles with the reverse sequence. Delayed recovery from hematological toxicities was treatment-limiting, with mainly moderate thrombocytopenia and neutropenia as dose-limiting toxicities for group A (5 of 10 patients for each) and thrombocytopenia for group B (3 of 6 patients). No febrile neutropenia or grade 3/4 non-hematological toxicity occurred. Pharmacokinetic analysis showed similar mean total platinum AUCs for the two groups: 37.2 ± 13.7 and 33.6 ± 9.9 mg·h/l, respectively. One complete response and two partial responses (World Health Organization–International Union Against Cancer criteria, response rate 18.8%) were seen in ovarian, Fallopian and neuroendocrine carcinomas, respectively.ConclusionsThis platinum combination appears feasible and active at the dose of AUC 4 mg·min/ml for carboplatin (Chatelut formula) and oxaliplatin 110 mg/m2; however, it does not allow a significant increase in platinum dose-intensity delivery." @default.
• W2096487127 created "2016-06-24" @default.
• W2096487127 creator A5002862341 @default.
• W2096487127 creator A5018514406 @default.
• W2096487127 creator A5021223452 @default.
• W2096487127 creator A5031166559 @default.
• W2096487127 creator A5041701219 @default.
• W2096487127 creator A5051029234 @default.
• W2096487127 creator A5055631929 @default.
• W2096487127 creator A5058262864 @default.
• W2096487127 date "2003-12-01" @default.
• W2096487127 modified "2023-10-11" @default.
• W2096487127 title "Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies" @default.
• W2096487127 cites W1550111394 @default.
• W2096487127 cites W1827936231 @default.
• W2096487127 cites W1857437878 @default.
• W2096487127 cites W1984351265 @default.
• W2096487127 cites W2007261008 @default.
• W2096487127 cites W2032553799 @default.
• W2096487127 cites W2033465919 @default.
• W2096487127 cites W2051667118 @default.
• W2096487127 cites W2052457410 @default.
• W2096487127 cites W2059547417 @default.
• W2096487127 cites W2065982243 @default.
• W2096487127 cites W2074519948 @default.
• W2096487127 cites W2113067724 @default.
• W2096487127 cites W2122731269 @default.
• W2096487127 cites W2128941960 @default.
• W2096487127 cites W2150870943 @default.
• W2096487127 cites W2162924104 @default.
• W2096487127 cites W2179956917 @default.
• W2096487127 cites W2226107060 @default.
• W2096487127 cites W2265340447 @default.
• W2096487127 cites W2267482046 @default.
• W2096487127 cites W2323681176 @default.
• W2096487127 cites W2587783403 @default.
• W2096487127 cites W2019124449 @default.
• W2096487127 doi "https://doi.org/10.1093/annonc/mdg490" @default.
• W2096487127 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14630684" @default.
• W2096487127 hasPublicationYear "2003" @default.
• W2096487127 type Work @default.
• W2096487127 sameAs 2096487127 @default.
• W2096487127 citedByCount "10" @default.
• W2096487127 countsByYear W20964871272015 @default.
• W2096487127 countsByYear W20964871272020 @default.
• W2096487127 countsByYear W20964871272021 @default.
• W2096487127 crossrefType "journal-article" @default.
• W2096487127 hasAuthorship W2096487127A5002862341 @default.
• W2096487127 hasAuthorship W2096487127A5018514406 @default.
• W2096487127 hasAuthorship W2096487127A5021223452 @default.
• W2096487127 hasAuthorship W2096487127A5031166559 @default.
• W2096487127 hasAuthorship W2096487127A5041701219 @default.
• W2096487127 hasAuthorship W2096487127A5051029234 @default.
• W2096487127 hasAuthorship W2096487127A5055631929 @default.
• W2096487127 hasAuthorship W2096487127A5058262864 @default.
• W2096487127 hasBestOaLocation W20964871271 @default.
• W2096487127 hasConcept C112705442 @default.
• W2096487127 hasConcept C121608353 @default.
• W2096487127 hasConcept C126322002 @default.
• W2096487127 hasConcept C126894567 @default.
• W2096487127 hasConcept C2776694085 @default.
• W2096487127 hasConcept C2777063308 @default.
• W2096487127 hasConcept C2778239845 @default.
• W2096487127 hasConcept C2778850193 @default.
• W2096487127 hasConcept C2780427987 @default.
• W2096487127 hasConcept C2780962732 @default.
• W2096487127 hasConcept C2781451048 @default.
• W2096487127 hasConcept C526805850 @default.
• W2096487127 hasConcept C71924100 @default.
• W2096487127 hasConcept C90924648 @default.
• W2096487127 hasConceptScore W2096487127C112705442 @default.
• W2096487127 hasConceptScore W2096487127C121608353 @default.
• W2096487127 hasConceptScore W2096487127C126322002 @default.
• W2096487127 hasConceptScore W2096487127C126894567 @default.
• W2096487127 hasConceptScore W2096487127C2776694085 @default.
• W2096487127 hasConceptScore W2096487127C2777063308 @default.
• W2096487127 hasConceptScore W2096487127C2778239845 @default.
• W2096487127 hasConceptScore W2096487127C2778850193 @default.
• W2096487127 hasConceptScore W2096487127C2780427987 @default.
• W2096487127 hasConceptScore W2096487127C2780962732 @default.
• W2096487127 hasConceptScore W2096487127C2781451048 @default.
• W2096487127 hasConceptScore W2096487127C526805850 @default.
• W2096487127 hasConceptScore W2096487127C71924100 @default.
• W2096487127 hasConceptScore W2096487127C90924648 @default.
• W2096487127 hasIssue "12" @default.
• W2096487127 hasLocation W20964871271 @default.
• W2096487127 hasLocation W20964871272 @default.
• W2096487127 hasOpenAccess W2096487127 @default.
• W2096487127 hasPrimaryLocation W20964871271 @default.
• W2096487127 hasRelatedWork W130051642 @default.
• W2096487127 hasRelatedWork W1945820803 @default.
• W2096487127 hasRelatedWork W2000475715 @default.
• W2096487127 hasRelatedWork W2083491734 @default.
• W2096487127 hasRelatedWork W2122435248 @default.
• W2096487127 hasRelatedWork W2157370852 @default.
• W2096487127 hasRelatedWork W2560259057 @default.
• W2096487127 hasRelatedWork W3037387467 @default.
• W2096487127 hasRelatedWork W4312909839 @default.

• next